Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

HCl is ongoing and patients are being enrolled at 36 investigational sites worldwide.  A majority of the planned 60 subjects have been enrolled in the study. The Company expects to complete enrollment in the first half of 2011 and to report top line results from this study in the second half of 2011.

Amicus and GSK intend to commence an additional Phase 3 study (Study 012) in the first quarter of 2011. Study 012 will be an 18-month, randomized, open-label study comparing migalastat HCl to enzyme replacement therapy (ERT) in approximately 60 subjects. The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).

About Fabry DiseaseFabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A). The role of alpha-Gal A within the body is to break down a complex lipid called globotriaosylceramide (GL-3). Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. This accumulation of GL-3 is believed to cause the various symptoms of Fabry disease, including pain, kidney failure, and increased risk of heart attack and stroke.

It is currently estimated that Fabry disease affects approximately 5,000 to 10,000 people worldwide.

About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... ANGELES , May 26, 2015 Mr. ... his family, thanks President Barack Obama and President ... during the time of loss of Dr. Rongxiang Xu ... humanitarian and a leader ahead of his time, Dr. Xu,s ... the community leave a legacy that will not be forgotten. ...
(Date:5/26/2015)... NEW YORK , May 26, 2015 ... NVGN ), announced today that it will present at the ... New York City at the Grand Hyatt ... Kelly , Novogen Chairman and CEO, is scheduled to begin at ... To access the webcast, go to http://wsw.com/webcast/marcum3/nvgn . ...
(Date:5/25/2015)... 2015 The 2015 Market Research ... a professional and in-depth study on the current ... with a focus on the Chinese situation. ... research are Linde Industrial Gas, Basf, Air Products, ... Xinlong Group, Longsheng Group, Juhua Group, Wandali Gas, ...
(Date:5/22/2015)... Warren, NJ (PRWEB) May 22, 2015 ... a new white paper that explores the potential of ... industries. The white paper was developed to help life ... they can leverage data to gain critical business insights. ... generated large amounts of data driven by patient profiling, ...
Breaking Biology Technology:Dr. Rongxiang Xu, Beyond A Legend 2Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY), announced ... will participate in two separate presentations at the,BIO 2008 ... a corporate overview of the,Company on Tuesday, June 17th ... On Wednesday, June 18th at 4:00 p.m. PT, ...
... NEWARK, N.J., June 12 BioNeutral announced today ... kill anthrax,spores on contact. This chemical technology is ... responders in conjunction with any suspected anthrax,exposure. "The ... formulation in as little as 15 seconds," said ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... be presenting at the Business Forum during BIO ... being held at the San Diego Convention Center ... of Senesco, will deliver the,Company,s corporate presentation on ...
Cached Biology Technology:Oncolytics Biotech Inc. to Present at BIO 2008 International Convention 2BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism 2Senesco Technologies to Present at BIO 2008 Business Forum 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... of widespread genetic sequencing, the ability to edit and alter ... information within and how it guides biological function. ... issue of the journal GENETICS takes genome editing ... level of fine control and, importantly, the transmission of those ...
... device invented at UCLA that conducts kidney tests and ... the need for frequent office visits by people with ... The smartphone-based device was developed in the research ... and bioengineering at the UCLA Henry Samueli School of ...
... study confirms that exposure to low to moderate amounts ... Doses of about 120 parts per billion of arsenic ... safeproduced lung damage comparable to decades of smoking tobacco. ... This is the first population-based study to clearly ...
Cached Biology News:Unprecedented control of genome editing in flies promises insight into human development, disease 2Unprecedented control of genome editing in flies promises insight into human development, disease 3UCLA researchers invent portable device for common kidney tests 2Study adds lung damage to harmful effects of arsenic 2Study adds lung damage to harmful effects of arsenic 3Study adds lung damage to harmful effects of arsenic 4
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Biology Products: